Mizuho upgraded shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) from a hold rating to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports.
CRVS has been the topic of a number of other reports. LADENBURG THALM/SH SH lifted their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a report on Monday, September 16th. StockNews.com raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $10.83.
Read Our Latest Stock Report on CRVS
Corvus Pharmaceuticals Trading Up 1.6 %
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05. During the same period in the previous year, the company earned ($0.14) earnings per share. Research analysts predict that Corvus Pharmaceuticals will post -0.45 EPS for the current year.
Institutional Trading of Corvus Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Avity Investment Management Inc. lifted its position in Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after acquiring an additional 16,000 shares during the period. Towerview LLC lifted its position in Corvus Pharmaceuticals by 4.6% during the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after acquiring an additional 17,500 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter worth about $44,000. Marshall Wace LLP acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter worth about $136,000. Finally, Vanguard Group Inc. lifted its position in Corvus Pharmaceuticals by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock worth $2,658,000 after acquiring an additional 142,724 shares during the period. Institutional investors and hedge funds own 46.64% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Recommended Stories
- Five stocks we like better than Corvus Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Golden Cross Stocks: Pattern, Examples and Charts
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What is the Nikkei 225 index?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.